![]() |
市场调查报告书
商品编码
1463830
欧洲非侵入性通气面罩市场规模和预测、区域份额、趋势和成长机会分析报告范围:按介面、应用、用途、尺寸、材料、产品类型、最终用户和国家/地区Europe Noninvasive Ventilation Masks Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Interfaces, Application, Usage, Size, Material, Product Type, End User, and Country |
欧洲非侵入性通气口罩市场预计将从2022年的7.1983亿美元成长到2030年的10.7668亿美元;预计2022年至2030年复合年增长率为5.2%。
非侵入性通气 (NIV) 是透过面罩输送氧气(通气支持),无需气管内气道。 NIV 透过减少呼吸功和改善气体交换,提供与传统机械通气相当的生理益处。此介入措施被认为是治疗慢性阻塞性肺病、心源性肺水肿和其他呼吸系统疾病的有效治疗方法,且无併发症,如上呼吸道创伤、呼吸器相关性肺炎、呼吸肌无力和鼻窦炎。因此,呼吸系统疾病的日益普及可能会严重影响未来几年欧洲非侵入性通气口罩市场的预测。
慢性阻塞性肺病盛行率上升推动欧洲无创通气面罩市场成长
慢性阻塞性肺病(COPD)是最重要的公共卫生议题之一。根据美国国家医学图书馆2022年发表的《德国慢性阻塞性肺病患者家庭远距监测计画的有效性》一文,德国报告约600万例慢性阻塞性肺病病例。一篇题为「体弱的瑞士人对慢性阻塞性肺病了解多少?」的文章指出。 2021 年发布的报告显示,瑞士约有 40 万人受到慢性阻塞性肺病 (COPD) 的影响。
患有潜在慢性阻塞性肺病且病情恶化、高碳酸血症性呼吸困难或呼吸衰竭的患者最有可能透过非侵入性通气 (NIV) 成功治疗。 NIV有效缓解呼吸肌肉压力,增加潮气量,降低呼吸频率,减少横膈呼吸做功,进而改善供氧,减少高碳酸血症,改善呼吸困难。 COPD 是 NIV 的理想选择,因为治疗可快速逆转,并且可以提供额外的支持。
NIV 可降低 COPD 患者的气管插管率、住院时间、机械通气併发症和死亡率。最近的临床实践指南推荐 NIV 作为治疗 COPD 急性呼吸衰竭 (ARF) 的第一线通气支持。 NIV 面罩越来越多地用于治疗慢性阻塞性肺病和呼吸衰竭患者。
NIV 有助于减少 COPD 恶化并伴随呼吸衰竭的患者的插管和死亡率。面罩的类型可能会影响成功率。对于病情严重且患有 ARF 的患者,建议使用全面罩而不是鼻罩。因此,欧洲慢性阻塞性肺病和其他呼吸系统疾病盛行率的增加预计将推动市场的成长。
口腔、口鼻、混合、鼻、鼻枕、头盔、头套和其他面罩类型可导致患者不适、漏气、幽闭恐惧症、皮肤发红、眼睛刺激、皮肤破损和儿童脸部畸形。面罩底部的小洩漏不会影响 NIV 的性能。然而,大量洩漏或面罩眼部洩漏可能会引起关注。鼻樑疼痛表示面罩太紧或顶部不合适。必须重新调整或更换面罩,因为疼痛会加剧。
由于这种干预措施的日益普及,与 NIV 面罩相关的压疮是一个重要的临床问题。压疮的发生与不良的临床结果、增加的併发症和延长的住院时间有关,所有这些都会加剧急性疾病的后果。
确保面罩正确贴合至关重要。否则,氧气可能会洩漏到眼睛中,引起刺激和结膜炎。使用全面罩可以干扰咳嗽并有效消除分泌物。此外,产生的过大压力会影响患者产生足够呼气流速的能力,进而对分泌物的动员和咳嗽阻力产生不利影响,进而导致分泌物滞留。
因此,与 NIV 面罩相关的副作用阻碍了欧洲非侵入性通气面罩市场的成长。
欧洲非侵入性通气面罩市场分析是透过考虑以下部分进行的:介面、应用、用途、材料、尺寸、产品类型和最终用户。从介面来看,市场分为口罩和配件。面罩部分包括鼻罩、面罩、鼻枕面罩、口腔面罩和全面罩/头盔。面罩进一步细分为二氧化碳排放面罩和非排放面罩。 NIV 面罩的配件包括弯头和替换弯头、软管、管子、皮肤屏障、鼻下/鼻垫以及头带/替换装备。根据应用,欧洲非侵入性通气面罩市场分为呼吸功能障碍、慢性阻塞性肺病、肺炎等。根据用途,市场进一步细分为儿科和成人。欧洲无创通气口罩市场进一步按规模细分为大、中、小型。依材质又可分为硅胶、凝胶等。根据产品类型,市场分为一次性和可重复使用。根据最终用户,市场分为医院、重症和急诊护理机构、门诊手术中心等。欧洲非侵入性通气口罩市场报告的范围包括评估英国、德国、法国、奥地利、瑞士和欧洲其他地区的市场表现。
欧盟(EU)和世界卫生组织(WHO)是准备欧洲非侵入性通气口罩市场报告时提到的主要主要和次要来源。
The Europe noninvasive ventilation masks market is expected to grow from US$ 719.83 million in 2022 to US$ 1,076.68 million by 2030; it is anticipated to record a CAGR of 5.2% from 2022 to 2030.
Non-invasive ventilation (NIV) is the delivery of oxygen (ventilation support) through a face mask, eliminating the need for an endotracheal airway. NIV provides comparable physiological benefits to conventional mechanical ventilation by reducing breathing work and improving gas exchange. The intervention is recognized as an effective treatment for respiratory failure in chronic obstructive pulmonary disease, cardiogenic pulmonary edema, and other respiratory conditions without complications, such as upper airway trauma, ventilator-associated pneumonia, respiratory muscle weakness, and sinusitis. Thus, the increasing prevalence of respiratory diseases will likely significantly impact the Europe noninvasive ventilation masks market forecast in the next few years.
Rising Prevalence of COPD Propels Europe Noninvasive Ventilation Masks Market Growth
Chronic obstructive pulmonary disease (COPD) is one of the most significant public health concerns. According to the article "Effectiveness of a home telemonitoring program for patients with chronic obstructive pulmonary disease in Germany" published by the National Library of Medicine in 2022, Germany reported ~ 6 million COPD cases. According to an article titled "What knows a frail Swiss population about chronic obstructive pulmonary disease?" published in 2021, about 400,000 people were affected by COPD in Switzerland.
Patients with underlying COPDs who suffer from exacerbation of their diseases and hypercapnic dyspnoea or respiratory failure are most likely to be successfully treated with noninvasive ventilation (NIV). NIV effectively relieves the pressure on the respiratory muscles, increases tidal volume, decreases respiratory rate, and reduces the work of diaphragmatic breathing, resulting in an improvement in oxygen supply, a decrease in hypercapnia, and an improvement in dyspnea. A COPD is ideal for NIV as the treatment is quickly reversible, and additional support can be provided.
NIV reduces the endotracheal intubation rate, length of hospital stays, complications of mechanical ventilation, and mortality for COPD patients. Recent clinical practice guidelines recommend NIV as first-line ventilatory support for treating acute respiratory failure (ARF) in COPDs. NIV masks are increasingly used to treat people suffering from COPD and respiratory failure.
NIV helps reduce intubation and mortality in patients affected by COPD exacerbation with respiratory failure. The type of mask may impact the success rate. A full-face mask is recommended over nasal masks for patients who are seriously ill and suffer from ARF. Thus, Europe's increasing prevalence of COPD and other respiratory disorders is expected to fuel the market's growth.
Oral, oronasal, hybrid, nasal, nasal pillow, helmet, headgear, and other mask types can lead to patient discomfort, air leaks, claustrophobia, skin redness, eye irritation, skin breakdown, and facial deformity in children. A small leak at the bottom of the mask does not affect NIV's performance. However, a large leak or a leak in the eye of mask can be a concern. Pain on the nose bridge indicates that the mask is too tight or is poorly fitting at the top. The mask must be readjusted or replaced, as the pain can worsen.
Pressure ulcers associated with NIV masks are a significant clinical problem due to the increasing popularity of the intervention. The development of pressure ulcers is associated with poor clinical outcomes, increased complications, and extended hospital stays, all of which aggravate the consequences of acute illness.
It is essential to make sure that the mask fits properly. Otherwise, oxygen may leak into the eyes, causing irritation and conjunctivitis. Using a full-face mask can interfere with coughing and effectively eliminate secretions. In addition, the excess pressure generated can affect the patient's ability to generate sufficient expiratory flow rates, adversely impacting the mobilization of secretions and cough resistance that leads to the retention of secretions.
Thus, side effects associated with NIV masks hamper the growth of the Europe non-invasive ventilation masks market.
The Europe noninvasive ventilation masks market analysis has been carried out by considering the following segments: interfaces, application, usage, material, size, product type, and end user. By interfaces, the market is bifurcated into masks and accessories. The masks segment consists of a nasal mask, face mask, nasal pillow mask, oral mask, and total face mask/helmets. Face mask is further sub-segmented into CO2 venting face mask and non-vented face mask. Accessories of NIV masks include elbows and replacement elbows, hoses, tubes, skin barriers, under/over the nose cushions, and head strap/replacement gears. Based on application, the Europe non-invasive ventilation masks market is segmented into respiratory dysfunction, chronic obstructive pulmonary disease, pneumonia, and others. Based on the usage, the market is further segmented into pediatrics and adults. The Europe non-invasive ventilation masks market, by size, is further segmented into large, medium, and small. Based on material, it is further segmented into silicon, gel, and others. Based on product type, the market is bifurcated into single-use and reusable. Based on end user, the market is segmented into hospitals, critical and acute care settings, ambulatory surgical centers, and others. The scope of Europe noninvasive ventilation masks market report includes assessing the market performance in the UK, Germany, France, Austria, Switzerland, and the Rest of Europe.
European Union (EU) and World Health Organization (WHO) are key primary and secondary sources referred to while preparing the report on the Europe noninvasive ventilation masks market.
Note - Similar information would be provided for below list of companies